Zacks Investment Research Lowers argenx SE (ARGX) to Hold

argenx SE (NASDAQ:ARGX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday, October 25th.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

Separately, Cowen and Company reissued a “buy” rating on shares of argenx SE in a research note on Thursday, August 24th.

Shares of argenx SE (ARGX) traded up $1.43 during midday trading on Wednesday, hitting $24.15. 17,300 shares of the company’s stock traded hands, compared to its average volume of 45,818. argenx SE has a 12 month low of $17.33 and a 12 month high of $27.25.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Lowers argenx SE (ARGX) to Hold” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://ledgergazette.com/2017/11/13/zacks-investment-research-lowers-argenx-se-adr-argx-to-hold.html.

A number of large investors have recently bought and sold shares of ARGX. Nicholas Investment Partners LP acquired a new stake in shares of argenx SE in the second quarter worth $236,000. DAFNA Capital Management LLC acquired a new stake in shares of argenx SE in the second quarter worth $848,000. Artal Group S.A. acquired a new stake in shares of argenx SE in the third quarter worth $1,229,000. Tekla Capital Management LLC acquired a new stake in shares of argenx SE in the second quarter worth $1,591,000. Finally, AWM Investment Company Inc. acquired a new stake in shares of argenx SE in the second quarter worth $2,121,000. 24.70% of the stock is currently owned by institutional investors.

argenx SE Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on argenx SE (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for argenx SE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx SE and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply